Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting
02 Février 2023 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat and prevent within
the field of hearing loss disorders, is pleased to announce its
participation, in-person, in the Association for Research in
Otolaryngology (ARO) 46th Annual MidWinter Meeting, taking place on
February 11-15, 2023, in Orlando, Florida, United States.
Laurent Désiré, PhD, Preclinical Development Director, and
Arnaud Giese, PhD, Group Leader - Animal Pharmacology Platform,
will co-present two posters during the Association for Research
in Otolaryngology (ARO) 46th MidWinter Meeting, taking place on
February 11-15, 2023, in Orlando, Florida, United States. The
poster abstracts are accessible by entering their title on the ARO
MidWinter Meeting website:
- “Preclinical Development of an Adeno-Associated Vector-Based
Gene Therapy (SENS-501) for the Autosomal Recessive Non-Syndromic
Deafness 9 (DFNB9)”
- “An Integrated Adeno-Associated Vector Development Platform
for Inner Ear Disorders”
Furthermore, Arnaud Giese, PhD, will co-chair a podium session
entitled “Inner Ear Therapeutics”. The session will take
place on February 12, 2023, 8 am – 10 am EST (2 pm – 4 pm CET), in
the Crystal Ballroom D-E.
The agenda of the conference can be found here.
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which
specializes in the development of novel therapies to restore, treat
and prevent hearing loss disorders, a significant global unmet
medical need.
Sensorion has built a unique R&D technology platform to
expand its understanding of the pathophysiology and etiology of
inner ear related diseases, enabling it to select the best targets
and mechanisms of action for drug candidates. Its portfolio
combines both small molecule and inner ear gene therapies
programs.
Its clinical-stage portfolio includes one Phase 2 product:
SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of
Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity
(CIO) and, with partner Cochlear Limited, in a study of SENS-401 in
patients scheduled for cochlear implantation. A Phase 2 study of
SENS-401 was also completed in Sudden Sensorineural Hearing Loss
(SSNHL) in January 2022.
Sensorion pursues its broad strategic collaboration with
Institut Pasteur focused on the genetics of hearing. It has two
gene therapy programs aimed at correcting hereditary monogenic
forms of deafness including OTOF-GT, targeting deafness caused by
mutations of the gene encoding for otoferlin, and hearing loss
related to mutations in GJB2 gene to potentially address important
hearing loss segments in adults and children (GJB2-GT). The Company
is also working on the identification of biomarkers to improve
diagnosis of these underserved illnesses.
www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer
This press release contains certain forward-looking statements
concerning Sensorion and its business. Such forward looking
statements are based on assumptions that Sensorion considers to be
reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
2021 full year financial report published on April 28, 2022, and
available on our website and to the development of economic
conditions, financial markets and the markets in which Sensorion
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Sensorion or not
currently considered material by Sensorion. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Sensorion to be
materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230201005815/en/
Investor Relations Noemie Djokovic Investor Relations and
Communications +33 6 76 67 98 31
ir.contact@sensorion-pharma.com
International Media Relations Consilium Strategic
Communications Matthew Cole/Jessica Hodgson +44 7593 572720 +44
7561 424788 Sensorion@consilium-comms.com
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sensorion (EU:ALSEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024